Skip Navigation



Carcinogenesis Advance Access published online on August 2, 2006

Carcinogenesis, doi:10.1093/carcin/bgl125
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
28/1/207    most recent
bgl125v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kushman, M. E.
Right arrow Articles by Townsend, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kushman, M. E.
Right arrow Articles by Townsend, A. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received July 19, 2005
Revised May 16, 2006
Accepted June 23, 2006

CARCINOGENESIS

Expression of human glutathione S-transferase P1 confers resistance to benzo[a]pyrene or benzo[a]pyrene-7,8-dihydrodiol mutagenesis, macromolecular alkylation, and formation of stable N2-Gua-BPDE adducts in stably transfected V79MZ cells co-expressing hCYP1A1

Mary E. Kushman 1, Sandra L. Kabler 2, Melissa H. Fleming 2, Srivani Ravoori 3, Ramesh C. Gupta 4, Johannes Doehmer 5, Charles S. Morrow 1, and Alan J. Townsend 1 *

1 Department of Biochemistry, Wake Forest University, Winston-Salem NC, USA 27157; Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University, Winston-Salem NC, USA 27157
2 Department of Biochemistry, Wake Forest University, Winston-Salem NC, USA 27157
3 James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40292
4 James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY 40292; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292
5 GenPharmTox BioTech AG, Munich, Germany

* To whom correspondence should be addressed.
Alan J. Townsend, E-mail: atown{at}wfubmc.edu


   Abstract

Transgenic cell lines were constructed to study dynamic competition between activation versus detoxification of benzo[a]pyrene (B[a]P) and its metabolites. Transfected V79MZ cells expressing human cytochrome P4501A1 (hCYP1A1) alone, or expressing hCYP1A1 in combination with human glutathione S-transferase P1 (hGSTP1), were used to determine how effectively GST protects against macromolecular damage or mutagenicity of B[a]P or its enantiomeric dihydrodiol metabolites (+)-benzo[a]pyrene-7,8-dihydrodiol ((+)B[a]P-7,8-diol) and (-)-benzo[a]pyrene-7,8-dihydrodiol ((-)-B[a]P-7,8-diol). Mutagenicity of B[a]P at the hprt locus was dose- and time-dependent in cells that expressed hCYP1A1. Mutagenicity was reduced in cells further modified to co-express hGSTP1. Dose-response and time course studies indicated that mutagenicity was reduced up to 3-fold by hGSTP1 expression, compared to cells expressing hCYP1A1 alone. Mutagenicity induced by the B[a]P 7,8-dihydrodiols was also dose-dependent, and was reduced 2- to 5-fold by hGSTP1. Expression of hGSTP1 reduced B[a]P adducts in total cellular macromolecules by 3.8-fold, which correlated with the reduction in B[a]P mutagenicity and with reduction in the formation of the proximate metabolite B[a]P 7,8-dihydrodiols from B[a]P. However, measurement of total B[a]P metabolites bound to DNA isolated from cells incubated with [3H]-B[a]P revealed only 12%, 33%, and 24% reduction at 12, 24 and 48 hours, respectively, by GSTP1 expression. Nevertheless, 32P-postlabeling analysis demonstrated nearly total prevention of the known B[a]P-DNA adduct, N2-guanine-BPDE, in cells co-expressing hGSTP1. This adduct, thought to be the most mutagenic of the stable B[a]P adducts, accounts for 15% or less of the total DNA adducts observed. These results indicate that the reduction in hCYP1A1-mediated B[a]P mutagenesis by hGSTP1 is likely due largely to prevention of the N2-guanine-BPDE adduct. However, the significant fraction (30-40%) of this mutagenesis and the majority of the total DNA binding that are not prevented, together suggest formation by hCYP1A1 of a subset of mutagenic metabolites of B[a]P that are not effectively detoxified by hGSTP1.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol SciHome page
M. E. Kushman, S. L. Kabler, S. Ahmad, J. Doehmer, C. S. Morrow, and A. J. Townsend
Protective Efficacy of hGSTM1-1 against B[a]P and (+)- or ( )-B[a]P-7,8-Dihydrodiol Cytotoxicity, Mutagenicity, and Macromolecular Adducts in V79 Cells Coexpressing hCYP1A1
Toxicol. Sci., September 1, 2007; 99(1): 51 - 57.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M. Tsai-Turton, B. N Nakamura, and U. Luderer
Induction of Apoptosis by 9,10-Dimethyl-1,2-Benzanthracene in Cultured Preovulatory Rat Follicles Is Preceded by a Rise in Reactive Oxygen Species and Is Prevented by Glutathione
Biol Reprod, September 1, 2007; 77(3): 442 - 451.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.